Boron neutron capture therapy(BNCT)is a radiotherapy modality based on nuclear capture and nuclear fission reactions.Boronophenylalanine(BPA)is a most widely tumor cell-selective boron carrier drug in the application of BNCT.Currently,many BPA-BNCT clinical trials have been conducted in treating brain tumors,melanoma,and head and neck tumors,which effectiveness has been confirmed to a certain extent.In order to improve the curative efficacy of BPA-BNCT,a number of studies have explored many kinds of treatment modalities included the combination of BPA and other boron-carrying drugs,the combination of BPA-BNCT and chemotherapeutic agents or the combination of BPA-BNCT and radiation therapy,but it is still questionable in terms of the prognostic improvement ability of the above treatment modalities on patients with tumors.At present,the development of BPA-BNCT is limited by boron-carrying drugs and neutron equipment,but the applied prospect of BNCT is very broad with the development of the third-generation boron-carrying drugs and the success of the construction of accelerator-based BNCT(AB-BNCT).This paper reviewed the new progress of BPA-BNCT in clinical research for multiple malignant tumors,and explored the facing opportunities and challenges of BNCT in clinical research.
维普
万方数据